IndustryCompany release

Prothena reports Q3 loss of $16.5m as partnered amyloid and Parkinson's programmes advance

🇺🇸 Prothena Corp Public Ltd Co (PRTA) · Thu 05 Nov 2026

The company ended the quarter with $272.2m in cash, while partners Novo, Roche and Bristol Myers Squibb progress late- and mid-stage trials.

Prothena reported third-quarter 2026 results on 5 November, posting a net loss of $16.5 million. Cash at the end of the quarter stood at $272.2 million.

Partner Novo presented post hoc Phase 2 data for coramitug at the Heart Failure Society of America (HFSA) meeting. In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), high-sensitivity C-reactive protein (hsCRP) fell with coramitug, whereas it rose in the placebo group.

Phase 3 trials of coramitug and of Roche's prasinezumab are ongoing. Primary completion for both is expected in 2029. Bristol Myers Squibb, which is developing moponetug, expects to report Phase 2 data in the first half of 2027.

Post hoc analyses are run after a trial has read out and are generally regarded as hypothesis-generating rather than confirmatory. The summary provided does not give further detail on the size of the hsCRP effect or on the analysis population.

What it means for your team

  • Late-stage readouts for coramitug and prasinezumab are not expected before 2029, so no near-term regulatory filings from these Phase 3 programmes should be assumed.
  • The hsCRP finding is a post hoc Phase 2 observation; teams should treat it as exploratory until confirmed in prospective data.
  • Bristol Myers Squibb's Phase 2 moponetug data, due in the first half of 2027, is the next announced clinical milestone among the partnered programmes.

Company's press release (SEC filing): Prothena Corp Public Ltd Co ↗

Article written by VigiEye from the official source (Prothena Corp Public Ltd Co). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →